obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid.
June 2017 decisions news release The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today published advice accepting four new medicines for routine use by NHSScotland.
